Neuronetics, Inc. (STIM) News
Filter STIM News Items
STIM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
STIM News Highlights
- For STIM, its 30 day story count is now at 3.
- Over the past 16 days, the trend for STIM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about STIM are DEC and DRUG.
Latest STIM News From Around the Web
Below are the latest news stories about NEURONETICS INC that investors may wish to consider to help them evaluate STIM as an investment opportunity.
Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement AccessoryNew accessory for NeuroStar TMS reduces patient setup steps and improves efficiency for providersMALVERN, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the U.S. Food and Drug Administration 510(k) clearance of NeuroSite™ Coil Placement Accessory, a state-of-the-art tool that simplifies measu |
NeuroStar TMS Receives Expanded Regulatory Approval in JapanTechnological advances reduce time and increase efficiency for MDD treatmentMALVERN, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved multiple proprietary innovations, which significantly advance the patient treatm |
Investors in Neuronetics (NASDAQ:STIM) from five years ago are still down 90%, even after 40% gain this past weekThis month, we saw the Neuronetics, Inc. ( NASDAQ:STIM ) up an impressive 77%. But that doesn't change the fact that... |
Neuronetics to Present at the 35th Annual Piper Sandler Healthcare ConferenceMALVERN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the 35th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. The Company is scheduled to present at 2:00 pm Eastern Time the same day via webcast. A live audio webcas |
NeuroStar Elevates Depression Treatment with Cutting-Edge Technology AdvancementsNew updates designed to advance practice efficiency and patient outcomesMALVERN, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced significant updates to the NeuroStar software and TrakStar® Patient Data Management System, a proprietary, HIPAA-compliant, patient management and outcomes reporting |
Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy CoveragePolicy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered LivesMALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced healthcare policy updates from Magellan, BlueCross BlueShield (BCBS) of Kansas City, and Dean Health Plan that inc |
Neuronetics, Inc. (NASDAQ:STIM) Q3 2023 Earnings Call TranscriptNeuronetics, Inc. (NASDAQ:STIM) Q3 2023 Earnings Call Transcript November 7, 2023 Neuronetics, Inc. misses on earnings expectations. Reported EPS is $-0.33 EPS, expectations were $-0.3. Operator: Good day, and thank you for standing by. Welcome to the Neuronetics Third Quarter 2023 Conference Call. [Operator Instructions] Please be advised that today’s conference call is being recorded. […] |
Neuronetics Inc (STIM) Reports 8% Revenue Growth in Q3 2023International Revenue Soars by 165% Year Over Year |
Neuronetics Reports Third Quarter 2023 Financial and Operating ResultsMALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2023. Third Quarter 2023 Highlights Third quarter 2023 revenue of $17.9 million, an increase of 8% over the third |
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 18,000 shares of the Company’s common stock (RSUs) to four new non-executive employees. In accordance with NASDAQ Listing Rule 563 |